This HEAL Initiative grant aims to promote the discovery and rigorous validation of novel therapeutic targets for developing pain treatments. The focus is on basic science within the peripheral/central nervous systems, immune system, or other tissues. Supported projects must identify targets leading to treatments with minimal side effects and low abuse/addiction potential, requiring robust validation studies to ensure reliability. This funding is broadly applicable across diverse pain conditions—like acute, chronic, migraine, or neuropathies—and encourages research targeting specific populations, including women, children, older adults, or underrepresented groups, to improve pain management.
Opportunity ID: 337273
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-22-034 |
| Funding Opportunity Title: | HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Food and Nutrition Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 07, 2022 |
| Last Updated Date: | Jan 07, 2022 |
| Original Closing Date for Applications: | Dec 06, 2024 |
| Current Closing Date for Applications: | Dec 06, 2024 |
| Archive Date: | Jan 11, 2025 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities State governments Small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-034.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 337273 Full Announcement-RFA-NS-22-034 -> RFA-NS-22-034-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00271275 | Feb 02, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00277895 | Nov 01, 2022 | Jan 24, 2025 | View |
Package 1
Mandatory forms
337273 RR_SF424_5_0-5.0.pdf
337273 PHS398_CoverPageSupplement_5_0-5.0.pdf
337273 RR_OtherProjectInfo_1_4-1.4.pdf
337273 PerformanceSite_4_0-4.0.pdf
337273 RR_KeyPersonExpanded_4_0-4.0.pdf
337273 PHS398_ResearchPlan_4_0-4.0.pdf
337273 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
337273 RR_Budget_3_0-3.0.pdf
337273 RR_SubawardBudget30_3_0-3.0.pdf
337273 PHS398_ModularBudget_1_2-1.2.pdf
337273 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
337273 RR_SF424_5_0-5.0.pdf
337273 PHS398_CoverPageSupplement_5_0-5.0.pdf
337273 RR_OtherProjectInfo_1_4-1.4.pdf
337273 PerformanceSite_4_0-4.0.pdf
337273 RR_KeyPersonExpanded_4_0-4.0.pdf
337273 PHS398_ResearchPlan_5_0-5.0.pdf
337273 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
337273 RR_Budget_3_0-3.0.pdf
337273 RR_SubawardBudget30_3_0-3.0.pdf
337273 PHS398_ModularBudget_1_2-1.2.pdf
337273 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
